Stay updated with breaking news from Nasdaq Afmd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Affimed (NASDAQ:AFMD – Get Rating) – Equities researchers at HC Wainwright increased their Q2 2023 earnings estimates for Affimed in a research report issued on Wednesday, May 24th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will earn ($0.23) per share for the quarter, up from their previous estimate of ($0.25). HC […]
Affimed (NASDAQ:AFMD – Get Rating) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average […]
StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Get Rating) in a research note released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. Other analysts have also issued reports about the company. Wells Fargo & Company reiterated an overweight rating and set a $7.00 price target on shares of […]
Research analysts at StockNews.com started coverage on shares of Affimed (NASDAQ:AFMD – Get Rating) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Several other analysts have also recently commented on AFMD. Stifel Nicolaus reduced their price target on Affimed from $2.00 to $1.00 […]
Affimed (NASDAQ:AFMD – Get Rating) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 23rd. Analysts expect Affimed to post earnings of ($0.22) per share for the quarter. Affimed (NASDAQ:AFMD – Get Rating) last posted its quarterly earnings results on Thursday, March 23rd. The biopharmaceutical company reported ($0.22) earnings […]